ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ATHE vs ANVS // ALTMAN Z-SCORE & DEBT/EQUITY

Alterity Therapeutics Limited (NASDAQ) VS. Annovis Bio Inc. (NYSE) • 15-METRIC TALLY: ATHE 0 — ANVS 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATHE VS. ANVS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ATHE ANVS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality — 1/9 — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 25.6 51.7 -26.13 ANVS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $40.7M $43.5M -$2.9M ANVS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ATHE REV ANVS REV ATHE GROSS % ANVS GROSS % ATHE FCF ANVS FCF
FY 2025 — $0 — — — -$25.6M
FY 2024 — $0 — — — -$21.9M
FY 2023 — $0 — — — -$40.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATHE // BETA —
ANVS // BETA —